文献速递其他结缔组织病

抗致密细斑点70(DFS70)抗体不一定能排除结缔组织病

Autoantibodies to dense-fine-speckled 70 (DFS70) do not necessarily rule out connective tissue diseases.
PubMed 文献 · Semin Arthritis Rheum · 2021-12-30

该研究分析了德国波恩大学医院460例接受抗DFS70抗体检测的患者,其中182例诊断为结缔组织病(CTD)。抗DFS70阳性患者中25.9%仍患有CTD,且抗DFS70阳性与阴性CTD患者在年龄、性别、症状、体征及其他疾病特异性抗体方面无显著差异。抗DFS70在ANA滴度≥1:160时对排除CTD的敏感性为26.9%、特异性为86.8%、阳性预测值为68.2%。作者认为抗DFS70在CTD患者中似乎普遍存在,因此不是良好的排除标准,但单特异性出现可能有助于判断疑难情况。

要点

  • 抗DFS70阳性患者中25.9%仍诊断为CTD。
  • 抗DFS70阳性与阴性CTD患者临床特征无显著差异。
  • 抗DFS70在ANA≥1:160时排除CTD的敏感性26.9%、特异性86.8%、阳性预测值68.2%。

核心结论

  • 抗DFS70抗体似乎在CTD患者中普遍存在,因此不是良好的排除标准;但单特异性出现可能有助于判断疑难情况。

研究设计与样本

  • 分析德国波恩大学医院460例接受抗DFS70检测患者的数据,评估临床症状与体征、疾病类型、CTD类型、分类标准满足情况、抗DFS70、其他系统性自身抗体及间接免疫荧光(IIF)和线性免疫印迹法检测的ANA滴度。

主要发现

  • 460例患者中182例(79.8%为女性)诊断为CTD;354例(77.0%)抗DFS70阴性,81例(17.6%)阳性,25例(5.4%)临界。
  • 抗DFS70阳性患者中21例(25.9%)患有CTD;抗DFS70阳性与阴性CTD患者在年龄、性别、症状、临床体征及其他疾病特异性抗体方面无显著差异。
  • 上述21例中仅1例呈现抗DFS70单特异性。

关键数值与推荐

  • 抗DFS70在ANA滴度≥1:160时对排除CTD的敏感性为26.9%、特异性为86.8%、阳性预测值为68.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In some patients with antinuclear antibodies (ANA), a pattern called anti-dense-fine-speckled-70 antibody (anti-DFS70) can be detected. Presence of anti-DFS70 is less frequently observed in patients with connective tissue diseases (CTD) and is therefore used as an exclusion criterion by some rheumatologists. To date, however, it is unclear as to what extent the presence of an anti-DFS70 can reliably rule out CTDs. METHODS: Data of 460 patients who were tested for the presence of anti-DFS70 at University Hospital Bonn, Germany, were analyzed. Patients were examined with regard to clinical symptoms and signs, type of disease, type of CTD, fulfillment of the classification criteria, presence of anti-DFS70, other systemic autoantibodies and ANA titers by indirect immunofluorescence (IIF) assays and line immunoassays. Differences in DFS70 antibody status between patients with CTD were examined. In addition, specificity, sensitivity, and positive predictive values for different ANA titers were calculated. RESULTS: In 182 of the 460 patients (of whom 79.8% were female), CTD was diagnosed. 354 patients (77.0%) tested negative, 81 (17.6%) positive and 25 (5.4%) borderline for anti-DFS70. Twenty-one patients (25.9%) with a positive result had CTD. No significant differences were observed between anti-DFS70 positive and anti-DFS70 negative patients with CTD concerning age, gender, symptoms, clinical signs, and other disease-specific antibodies. However, of these 21 patients, only one patient showed the monospecific appearance of anti-DFS70. Anti-DFS70 had a sensitivity and a specificity of 26.9% and 86.8%, respectively, with a positive predictive value of 68.2% at an ANA titer of ≥1:160 with respect to the absence of CTD. CONCLUSIONS: Autoantibodies to DFS70 seem to be prevalent in CTD patients and are thus not a good exclusion criterion. The monospecific occurrence of anti-DFS70 can, however, be helpful in ambiguous situations.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Mockenhaupt LM, Dolscheid-Pommerich R, Stoffel-Wagner B, et al. Autoantibodies to dense-fine-speckled 70 (DFS70) do not necessarily rule out connective tissue diseases. Semin Arthritis Rheum. 2021. PMID: 35027246. doi:10.1016/j.semarthrit.2021.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。